EQT

EQT is a private equity firm based in Stockholm, Sweden, founded in 1994. The firm specializes in buyouts, expansion capital, and infrastructure investments, targeting mid-market companies with significant growth potential across Northern and Eastern Europe, Asia, and the United States. EQT employs a responsible ownership approach and focuses on four main investment strategies: private capital, which encompasses ventures and mid-market equity; real assets, including infrastructure and real estate; credit; and public value. The firm aims to acquire or finance high-quality companies and seeks to take controlling or co-controlling stakes, often engaging in sectors such as healthcare, technology, industrials, and consumer services. EQT maintains a global investment perspective, targeting opportunities that align with its industrial growth strategy while holding portfolio companies for an average duration of four to eight years.
Unit 1507-1508 CITIC Square 1168, Nanjing Road West, Shanghai 200041, China

Päivi Arminen

MD

Andreas Aschenbrenner

Partner

Michael Bauer

Partner, Investment Advisory Professional, Head of Switzerland and Co-Head of EQT's Global Healthcare Sector Team

Daniela Begolo

Managing Director

Ralph Betz

Director of Credit Team

Lennart Blecher

Deputy Managing Partner

Per Georg Braathen

Industrial Advisor

Marcus Brennecke

PARTNER and CO-HEAD OF EQT PRIVATE EQUITY ADVISORY TEAM

Carolina Brochado

Partner, Growth & Investment Advisory Professional

Nicolas Brugère

Partner and Head of France

Drew Burdon

Partner

Sarah Carr

Investor Relations Manager

Jay Chae

Director, Client Relations and Capital Raising (APAC)

Tak Wai Chung

Head of EQT Mid Market Southeast Asia and Partner

Hans Clevers

Venture Partner

Crosby Cook

Partner

Alex Darden

PARTNER

Johan Dettel

Partner

Mads M. Ditlevsen

Partner & Head of EQT Partners Denmark

Tracy Duong

VP

Victor Englesson

Partner

Matthias Fackler

PARTNER and HEAD OF EQT INFRASTRUCTURE ADVISORY TEAM EUROPE

David Forde

Managing Director,Private Equity

Per Franzén

Head of Private Capital and Deputy Managing Partner

Florian Funk

PARTNER

Anders Gaarud

Public Value Partner

Wolfgang Gorny

Partner, Private Equity

Simon Griffiths

PARTNER and HEAD OF PRIVATE EQUITY ASIA PACIFIC

Fabian Gröne

Partner, Head of Asia

Albert Gustafsson

PARTNER

Sean Ham

Managing Director, Client Relations and Capital Raising (APAC)

Adil Haque

Partner, Client Relations and Capital Raising (Americas)

Jerry He

PARTNER and HEAD OF CHINA, MID MARKET ASIA ADVISORY TEAM

Frank Heckes

PARTNER

Erika Henriksson

PARTNER

Bruno Holthof

Partner

Masoud Homayoun

PARTNER

Andreas Huber

Partner, Vice Chairperson Asia Pacific, Infrastructure

Morten Hummelmose

HEAD OF CLIENT RELATIONS and CAPITAL RAISING ADVISORY TEAM, PARTNER

Neha Jatar

Managing Director

Conni Jonsson

Founder and Chairperson

Matthew Kestenbaum

Managing Director

Jörg Kinberger

PARTNER

Harry Klagsbrun

PARTNER

Martijn Kleijwegt

Managing Partner and Founder

Thomas von Koch

Managing Partner and Chief Executive Officer

Nicolas Kollmann

Associate

Andrew Konopelski

Partner and Head of EQT Credit

Vesa Koskinen

PARTNER

Arvindh Kumar

Partner

Eugene Lee

DIRECTOR

Mikael Lilius

Industrial Advisor

Benjamin Lim

VP

Eric Liu

PARTNER and CO-HEAD OF GLOBAL HEALTHCARE SECTOR TEAM

Paola Maleh

Partner & Head of EMEA

Carlota Sanchez Marco

Investor Relations MD

Anders Misund

Partner, Private Equity & Head of Nordics

Arnav Mitra

Director

Martin Mok

Partner and Head of Mid Market Asia

Joep Muijrers

Partner

Jörg Neermann

Partner

Rikke Nielsen

PARTNER

Kristiaan Nieuwenburg

Chairman of EQT Partners & Head of Private Equity

Daniel Perez

PARTNER

Anne Portwich Ph.D

Partner

Arno Poschik

Director

Robert Rackind

PARTNER

Hermann Rauch

DIRECTOR

Paul de Rome

Partner and Head of Credit Team

Joachim Rothe Ph.D

Managing Partner & Partner

Rosa Sammon, Darlene De La

Managing Director, Client Relations and Capital Raising (Americas)

Carlota Sanchez-Marco

Managing Director, Investor Relations

Carlos Santana

Partner

Mika Saukkonen

MD

Christian Sinding

CEO and Managing Partner

Piyush Singhvi

MD

Georg Stadler

PARTNER

Dominik Stein

PARTNER

Anna Sundell

Partner

Angelo Syailendra

DIRECTOR

Tian Tan

VP

Erwin A. Thompson

PARTNER

Peter Veldman

Advisor and EFMS Board Member

Felice Verduyn

Partner

Jan Vesely

Partner

Marcus Wallinder

Partner & Deputy Head of Client Relations and Capital Raising

Forrest Wang

MD

Felice Verduyn-Van Weegen

Investment Associate

Frans Winarto

VP

Matthias Wittkowski

Partner

Ken Wong

PARTNER

James Yu

PARTNER

Julia Zhu

Managing Director

Fredrik Åtting

Partner

John Österlund

MD

582 past transactions

NewBiotics

Series C in 2001
NewBiotics transforms drug resistances into therapeutic advantages. It focuses on the discovery and development of drug molecules that leverage the cycle of drug resistance in both cancer and infectious diseases. NewBiotics is a U.S.-based company that was founded in 1997 and the company was acquired by Celmed Biosciences on June 7, 2004.

AM-Pharma B.V.

Private Placement in 2019
AM-Pharma B.V. is a biopharmaceutical company that develops and manufactures recombinant human alkaline phosphatase therapeutics for the treatment of acute kidney injury, inflammatory bowel disease, and hypophosphatasia. It offers recombinant human alkaline phosphatase in an injectable form for the treatment of acute kidney injury, as well as oral formulation for the treatment of ulcerative colitis. The company also offers Bovine AP, an alkaline phosphatase for the treatment of inflammatory bowel disease. AM-Pharma B.V. was founded in 2000 and is based in Bunnik, the Netherlands.

Kiadis Pharma

Venture Round in 2007
Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.

VarmX

Series B in 2020
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.

Merus

Series C in 2015
Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.

Heart Metabolics

Series A in 2014
Heart Metabolics Limited is pioneering a pharmaceutical therapy for the treatment of hypertrophic cardiomyopathy (“HCM”). HCM is a condition in which the heart muscle becomes thick. The thickening makes it harder for blood to leave the heart forcing the heart to work harder to pump blood, leading in many cases to heart failure. Sudden death is caused frequently. There are over 100,000 cases of HCM in the United States alone, often presenting more severely in young adults and athletes; unfortunately the younger the individual is when diagnosed with HCM, the more likely that the individual has a severe form. Although various cardiovascular drugs are currently used to treat HCM, there are patients who are not being helped by current therapeutics. In response to this medical need and based on encouraging phase II clinical trial results to date, Heart Metabolics is developing perhexiline as a therapeutic for all types of HCM. Perhexiline is currently an approved drug in Australia and New Zealand for the treatment of angina. Heart Metabolics plans to conduct clinical trials in the U.S. and seek FDA approval of perhexiline as an orphan drug; the company currently has such an orphan designation from the FDA.

Direct ChassisLink

Merger/Acquisition in 2016
Direct ChassisLink, Inc. (DCLI) was originally formed in 1988 as Maersk Container Service Company (MCSC), a maintenance and repair organization responsible for repairing containers, chassis, and refrigeration unit generator sets. In the late 1990’s the group was reorganized to accommodate an ever growing fleet of chassis and containers under the name Maersk Equipment Service Company (MESC). In 2007 with the continued growth of the chassis fleet, Maersk shifted container and refrigerator unit related repairs to another division and MESC became focused solely on chassis maintenance and leasing. In 2009 Maersk determined to divest itself of its chassis interests and MESC began using the DCLI brand and actively marketing chassis on a fee per day basis to motor carriers.

Xeltis

Series B in 2014
Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.

Amolyt Pharma

Series A in 2019
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

SUSE

Acquisition in 2018
SUSE Software Solutions Germany GmbH designs, develops, and offers Linux and open source solutions. The company's products includes Enterprise Linux, Run SAP, SUSE CaaS platform, SUSE DEOps, SUSE manager, and multi-cloud infrastructure. It offers maintenance, support and consulting services through recurring subscription fees. In addition, its partners include AWS, Cisco, Fujitsu, Hitachi, IBM, Intel, Lenovo, SAP, and VMware. The company was founded in 1992 and is based in Nuremberg, Germany.

Pharvaris

Series A in 2016
Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.

Rolls-Royce Power Systems

Acquisition in 2006
Rolls-Royce Power Systems AG with registered offices in Friedrichshafen is a specialist for large engines, propulsion systems and distributed energy systems, which operated previously under the name of Tognum AG. The core company is MTU Friedrichshafen, with its regional companies of MTU America in Novi, Michigan, USA, and MTU Asia in Singapore. Under the MTU brand, Rolls-Royce Power Systems markets large high-speed engines and propulsion systems for ships, for heavy land, rail and defence vehicles, and for the oil and gas industry. The product portfolio for distributed energy systems, which are marketed under the MTU Onsite Energy brand, includes diesel gensets for emergency, base load and peak load applications, in addition to cogeneration plants for the generation of combined heat and power based on gas engines and/or gas turbines. The Norwegian subsidiary Bergen Engines manufactures medium-speed diesel and gas engines for marine and power generation applications. Fuel injection systems manufactured by L'Orange are also included in the product portfolio.

Egle Therapeutics

Series A in 2021
Egle Therapeutics SAS, a biotechnology company, develops immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases. It develops Treg modulating drug pipeline, which includes computationally designed resurfaced IL-2 proprietary variants to engage or dis-engage Tregs. The company was founded in 2020 and is based in Paris, France.

Visus Therapeutics

Debt Financing in 2021
Visus Therapeutics is a clinical-stage company developing innovative medicines to improve the vision for people around the world.

Parkia

Acquisition in 2011
Parkia operates off-street car parking lots in Spain and Andorra. It offers services in the areas of car wash, car rental, engine jump-starter, elevator, CCTV control, payment, lactation room, ski trunk, charge point, discount coupon, advertising media, electronic invoicing, umbrella, map, personal and location, and breathalyzer aspects; snacks and drinks.

ActoGeniX

Private Equity Round in 2009
ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.

XyloCor Therapeutics

Venture Round in 2021
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patients with refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively.

Affectis Pharmaceuticals

Series A in 2003
Affectis is a pharmaceuticals company developing novel drugs for the treatment of neurodegenerative and neuroinflammatory diseases.

Kuros Biosciences

Post in 2015
Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s orthobiologics pipeline products comprise MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaborations with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is based in Schlieren, Switzerland.

Trinity Biosystems

Debt Financing in 2009
Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.

Segra

Acquisition in 2017
Lumos Networks Corp. is a fiber-based service provider in the Mid-Atlantic region. The Company provides data, broadband, voice and Internet protocol (IP) services over fiber optic network. The Company offers a range of data and voice products supported by approximately 5,800 fiber-route miles in Virginia, West Virginia, and portions of Pennsylvania, Maryland, Ohio and Kentucky. Its products and services include metro Ethernet, IP services, business advantage bundle, managed router service, broadband, voice services and Web hosting. On October 14, 2011, NTELOS Holdings Corp. announced a distribution date of October 31, 2011, for the spin-off of Lumos Networks Corp.

Sausalitos

Private Equity Round in 2008
Sausalitos is one of the leisure restaurant chains in Germany.

Vivasure Medical

Series C in 2016
Vivasure Medical Limited, a medical device company, engages in the research, development, and manufacture of arterial and venous closure devices based on its patented PerQseal technology. The company develops polymer implants and delivery systems that primarily focused on minimally invasive vessel closures in cardiology, interventional radiology, and vascular surgery areas. Its lead product is an absorbable patch-based large-bore percutaneous closure device that is designed to enable closure of large arteriotomies in transcatheter procedures, such as those used for transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR). Vivasure Medical Limited was incorporated in 2008 and is based in Galway, Ireland.

GlobalConnect

Acquisition in 2016
GlobalConnect is the leading alternative provider of fiber network, data center and managed hosting services in Denmark. The Company’s 12,500 km owned optical fiber network covers Denmark and Germany and it has approximately 13,000 sqm of data center space. GlobalConnect was founded in 1998 by Niels Zibrandtsen and employs more than 200 employees.

Merus

Post in 2018
Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.

Harvest Automation

Series A in 2010
Harvest was founded by a seasoned technology executive and a trio of robotics experts. The Company now comprises a diverse, commited team with expertise in sales and marketing, engineering (software, hardware, electrical, mechanical), project management, and business operations.

Parcel2Go

Acquisition in 2021
Parcel2go.Com Ltd provides parcel delivery services in the United Kingdom. Its services includes myHermes ParcelShop; allows to drop off parcel at one of many outlets hence saving having to wait in for the driver to collect, DPD Drop-off; allows to drop parcel off at any of the DPD locations around the UK, UPS Standard; recognizes parcel couriers with brown vans and uniforms, Parcelforce Worldwide 48; allows to drop parcel in to a local Post Office, TNT UK Express, and Letters and Small Parcels by Whistl. The company was founded in 1991 and is based in Bolton, United Kingdom.

NewBiotics

Series E in 2004
NewBiotics transforms drug resistances into therapeutic advantages. It focuses on the discovery and development of drug molecules that leverage the cycle of drug resistance in both cancer and infectious diseases. NewBiotics is a U.S.-based company that was founded in 1997 and the company was acquired by Celmed Biosciences on June 7, 2004.

Cardiac Dimensions

Series A in 2015
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

ImCheck Therapeutics

Private Placement in 2019
ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

Dojo

Debt Financing in 2018
Paymentsense is a financial technology company providing card payment solutions for small and medium-sized businesses in the UK and Ireland. From Contactless card machines to online payments and integrated services, Paymentsense supplies over 60,000 small businesses with card processing solutions that allow them to take payments in store, online, over the phone and on the move.

Pharvaris

Series B in 2019
Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.

ManyPets

Series D in 2021
Bought By Many is the multi-award-winning pet insurance provider that is disrupting insurance distribution. They do this by analysing anonymised internet search data and customer research to identify unmet consumer needs for insurance. Key company milestones are as follows: o 2012: Launched boughtbymany.com. Completed seed funding round. o 2013: Named Insurance Website of the Year. o 2014: Identified by Boston Consulting Group & Morgan Stanley as the global exemplar of innovation in insurance distribution. Awarded Best Use of Mobile Technology at the Digital Insurance Awards. o 2015: Surpassed 100,000 members. Launched SaaS platform in China in partnership with Ping An Insurance. Completed second funding round. Became directly regulated by the FCA. Acquired Brooks Braithwaite (Sussex) Ltd - the UK’s leading provider of insurance for exotic pets and pet businesses. Named Fintech Innovation of the Year & Insurance Start Up of the Year. o 2016: Innovation in Insurance Award at the Fintech Innovation Awards. Named in the FinTech 50. Signed long-term insurance agreement with Munich Re. Completed Series A funding round. o 2017: Launched Bought By Many-branded cat and dog insurance product range. o 2019: Named most trusted pet insurance provider at the 2019 Moneywise Customer Service Awards. Launched Bought By Many cat and dog insurance in Sweden. o 2020: Covers more than 200,000 pets in the UK. They have an exceptional team of 150, based across sites in Farringdon, Central London; Haywards Heath, Sussex; Birmingham; and Sweden. They're always interested to hear from people who'd like to learn about career opportunities at Bought By Many, and they're currently recruiting for web development, business analysis, & project management roles.

Pasteuria Bioscience

Series B in 2009
Pasteuria Bioscience, Inc. was founded in 2003 in the University of Florida's Sid Martin Biotechnology Incubator. The company was developed out of Entomos, Inc., to commercialize its revolutionary technology for production of nematode control products Pasteuria Bioscience has successfully raised over $6 million in venture funding in its series A and series B rounds, which has enabled the advancement of the technology to the point of commercial-scale production and EPA registration of its first product. This initial product will be for control of sting nematodes in professional turf, and is expected to launch in late 2009. Progress towards launch is supported by multiple ongoing turf field trials and other commercial development activities. The company also continues to build its pipeline of products and its intellectual property portfolio through a vigorous laboratory development program.

Harvest Automation

Series B in 2011
Harvest was founded by a seasoned technology executive and a trio of robotics experts. The Company now comprises a diverse, commited team with expertise in sales and marketing, engineering (software, hardware, electrical, mechanical), project management, and business operations.

GETEC

Acquisition in 2016
GETEC is a group of energy service providers active throughout Germany and Europe. With a workforce of almost 1,400 employees, the GETEC companies offer the complete range of energy services in the liberalised energy market. It ranges from Energy efficiency and System design to Zero emissions. For our clients, they act as pilot in an increasingly complex world of energy. They develop customised solutions, conceiving their concepts with a focus on the outcome and beyond “energy”. GETEC generates added value for its clients through comprehensive approaches and complete system solutions. In so doing, sustainability, efficiency, economic viability and conservation of their resources are the guiding principles of our corporate policies. We help our clients improve their carbon footprint, with a keen eye on the future – for the generations to come.

Binx Health

Series B in 2011
Binx Health Limited, an in vitro diagnostics company, develops and provides diagnostic instrument and disposable cartridge systems for decentralized laboratory, point-of–care, and other near-patient settings. It offers io System, a diagnostic platform that is designed to detect the presence of infectious diseases, such as chlamydia and MRSA; and Callisto, a system that provides a solution to meet a range of throughput requirements. The company provides solutions for sexually transmitted infections and hospital acquired infections. Binx Health Limited has a strategic partnership with Sherlock Biosciences. The company was founded in 2005 and is based in Trowbridge, United Kingdom.

Nouscom

Series A in 2016
Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.

Apleona

Acquisition in 2016
Apleona is an integrated Real Estate service provider in the DACH region with particular technical facility services. Its services include facility management, building technology, and interior fittings to real-estate management with all commercial services, letting, leasing, and marketing of real estate. It was formed in 2016 and headquartered in Neu Isenburg, Hessen.

Beijer Ref

Merger/Acquisition in 2020
Beijer Ref is a technology-oriented trading group that, through value-added products, offers its customers competitive solutions in refrigeration and air conditioning.

Mint Solutions

Series A in 2014
Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.

Colisée

Acquisition in 2020
Colisée is a key player in the global health care and old-age dependency sector, and has developed a real expertise in elderly people care and well-being. Its network includes 90 facilities in France, Italy and Spain and close to 70 home-based services agencies in France. In those two business segments, Colisée employs more than 6,700 people.

Iver AB

Merger/Acquisition in 2018
Candidator is a successful IT company which delivers complete IT operation, telephony and outsourcing services to companies and organisations on the Nordic market, under the motto "Make IT simple"​. Our strategy is to build long-term customer relationships by combining high levels of service with effective IT solutions which provide the customer with clear business benefits.

DESOTEC

Acquisition in 2017
Founded in 1990, Desotec has pioneered the market for the purification of liquids and gases through mobile activated carbon filters. During its more than 25 years in business, the company has established itself as a European market leader in this field. Desotec provides a filtration technology that enables its customers to comply with increased environmental regulations and sustainability requirements and to serve mission-critical filtration needs offering a flexible rental solution.

Oterra

Acquisition in 2020
Chr Hansen - Natural Colors is a developer and manufacturer of natural coloring ingredients for food and beverages.

StormGeo

Acquisition in 2014
StormGeo is a provider of data science and weather intelligence for a worldwide customer base with advanced solutions through our global 24/7 forecasting desks and R&D team. The company also provides operations in shipping, renewable energy, aviation, oil & gas, media, and cross-industry. Their customers operate in changing environments onshore, offshore, in the air and at sea. They staff eight forecast centers worldwide and have earned a reputation in the industry for high-quality forecasts, commitment to innovation through extensive research and development, and exceptional customer service. StormGeo was founded in 1998 and is based in Bergen, Norway.

Syntaxin

Series B in 2007
Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Swedegas

Acquisition in 2009
Swedegas AB engages in the investment, development, and maintenance of infrastructure for the distribution of gas. The company owns and runs the Swedish gas transmission network in Western Sweden; and serves as a transmission system operator for balancing the gas transmission system. It also offers gas connection and storage services. In addition, the company provides technical services, including investigation and measuring. It serves industries, households, and the transport sector. Swedegas AB was formerly known as Nova Naturgas AB and changed its name to Swedegas AB in 2007. The company was incorporated in 1973 and is headquartered in Gothenburg, Sweden. As of November 21, 2018, Swedegas AB operates as a subsidiary of FS Gas Transport AB.

Segra

Acquisition in 2018
Segra is one of the largest independent fiber bandwidth infrastructure companies in the U.S.

BMEYE

Series A in 2009
BMEYE B.V., a non-invasive cardiovascular monitoring company, engages in the research and development of medical technologies for cardiovascular monitoring in the Netherlands and internationally. It offers finger arterial pressure and cardiac output technologies. The company's products include Finapres, a non-invasive continuous finger blood pressure monitor; Portapres, an ambulatory non-invasive continuous finger blood pressure monitor for measurements; Finometer, a stationary monitor with options for non-invasive brachial pressure and beat-to-beat hemodynamics; and BeatScope, a software package for the analysis of arterial pressure waveforms. Its products also comprise Modelflow, a model-based measurement method to compute the aortic flow waveform and cardiac outout from an arterial blood pressure waveform; Space instrumentation, a version of finger blood pressure monitors; Cardiopres, an ambulatory device for research on the interaction of electrophysiology, hemodynamics, and respiration; and Oxyflow, a hemodynamics and oxygen delivery monitor for experimental applications. In addition, the company offers Nexfin, a non invasive blood pressure and cardiac output monitor, as well as ccNexfin for applications in various areas, such as cardiology, anesthesiology, sleep observation, physiology, neurology, and internal medicine; and emergency, acute, intensive, and intermediate care. It offers its products through a network of distributors. BMEYE B.V. was founded in 2005 and is based in Amsterdam, the Netherlands.

Aldevron

Merger/Acquisition in 2019
Aldevron provides contract manufacturing and scientific services. It specializes in plasmid DNA, protein production, and antibody generation. It combines best-in-class products and service with the ideal operating environment to lay the groundwork for vital new discoveries worldwide. Its services include Plasmid DNA Production, Protein Production, Antibody Discovery, mRNA Production, and other related services. It was founded in 1998 and is headquartered in Fargo, North Dakota, United States.

Anticimex AB

Venture Round in 2021
Anticimex is a global specialist in preventive pest control with operations in 17 counties across Europe, Asia-Pacific and the US with headquarters in Stockholm, Sweden. With its approximately 4,500 employees, Anticimex serves more than 3 million customers across the globe and offers a broad range of preventive pest control solutions, including the digital solution Anticimex SMART and pest insurance.

BSN Medical

Acquisition in 2012
BSN medical is a global leader in the worldwide healthcare market specialising in the areas of Compression Therapy, Wound Care and Orthopaedics. We are focused on the development of world-class branded products that offer high quality solutions for our caregivers and patients. BSN medical connects its broad portfolio in Wound Care & related Vascular Diseases, Lymphology and non-invasive Orthopaedics with strong technological competencies to meet the market's need for reduced complexity and more efficient treatments. With a continuously developing unique and holistic network integrated therapy solutions, BSN medical consistently supports a continuum of care.

Scandic Hotels Group

Acquisition in 2007
Scandic Hotels Group is a Sweden-based company that engages itself in operation of hotels. It operates more than 200 hotels at close to 120 destinations which give a unique geographic reach for both corporate and leisure travelers. The majority of the company revenue comes from business travel and conferences. The business of the group is operated through various geographical region which includes Sweden, Belgium, Denmark, Finland, Norway, Poland, and Germany out of which Sweden accounts for majority of revenue.

Eton

Acquisition in 2015
Eton AB manufactures and sells shirts and accessories for men worldwide. The company offers shirts in various categories, such as business, unbuttoned, casual, evening, and more; and accessories, including ties, pocket squares, bow ties, cufflinks and jewelry, and warming and other scarves. It offers products through department and its own stores, independent retailers, as well as online. The company was founded in 1928 and is headquartered in Gånghester, Sweden.

Antas

Private Equity Round in 2019
Antas s.r.l. anticipates the market needs, realising the concept of Facility Management in its structure. As a matter of fact, it establishes the new service standards, the reference point for the whole sector. One of the Gruppo Giglio feature is the ability of proposing itself as a 360° partner for the management of all support service activities for public and private companies. The wide experience and the know-how acquired allow the company to select, together with the customer, the best solutions possible, according to his specific features and needs.The technical experience developed and strengthen during these years allows Antas s.r.l. to supply a wide range of services to residential, industrial and tertiary public fields. Among these services we find: COMBINED ENERGY SERVICE, FACILITY MANAGEMENT, RENEWABLE ENERGIES, COGENERATION, PROJECT FINANCING and ENERGY EFFICIENCY.

IFS

Merger/Acquisition in 2016
IFS World Operations AB provides enterprise, manufacturing, service management, and asset management solutions. The company is based in Linköping, Sweden. IFS World Operations AB operates as a subsidiary of Industrial and Financial Systems, IFS AB (publ).

Sportradar

Merger/Acquisition in 2018
Sportradar is the world’s leading supplier of sports and betting-related data. Inspired by the passion and vision of a fast-growing staff with independent thinkers, Sportradar has developed into a key player providing all necessary data for the betting and sports media industry, such as fixtures, results, odds compiling and in-running services, as well as front-end content solutions like statistics and live scores. Alongside that, with their security services they work side-by-side with the leading international sport federations including UEFA and the German DFB/DFL. A combination of clever innovations, a strong desire to build quality applications and the ability to provide practical solutions means the venture still thrives today. Today the company is more than ever committed to actively shaping the future through close relationships with its customers. Company founder and CEO Carsten Koerl is the majority shareholder of Sportradar.

TransIP

Private Equity Round in 2016
TransIP Group B.V. provides virtual private servers, domain name registration, and Web hosting services to customers and information technology professionals. The company offers BladeVPS PureSSD Pro, a self-managed tool that contains Web control panels and operating systems; STACK, an online storage solution for storing, syncing, and sharing various files, photos, and documents; and SSL certificates that encrypt the connection between a Website and the server. It also offers forwarding, big storage, and private network services. The company was founded in 2003 and is based in Leiden, the Netherlands. As of May 23, 2019, TransIP Group B.V. operates as a subsidiary of Combell nv.

China F&B

Acquisition in 2013
China F&B operates two renowned international restaurant chains, Dairy Queen (DQ) and Papa John's Pizza (PPJ) in China, and is the world's largest franchisee of DQ and the largest franchisee of PPJ outside the United States. The Company was founded in 2003 and is today the largest ice cream restaurant chain and the second largest pizza restaurant chain in China. As of 31 December 2013, China F&B had a network of 407 DQ outlets and 140 PPJ outlets.

Depict

Seed Round in 2020
Depict.ai is building a product recommendation engine to help bring “Amazon-quality” product recommendation for any e-commerce store.

Dako Denmark

Acquisition in 2007
Dako Denmark A/S provides reagents, instruments, and software for cancer diagnostics to hospital and research laboratories worldwide. It offers pathology products, including reagents and antibodies; pharmacodiagnostic kits and pharmDx; staining instruments and instruments for image analysis; and systems where instruments, reagents, training, and service are integrated, which are used by pathologists for in vitro diagnostics to diagnose cancer and other chronic diseases on the basis of tissue samples. The company also provides flow cytometry products comprising reagents and accessories; instruments for flow cytometry; and systems that are used to analyze cells in blood and other fluids, and are employed in the diagnosis of leukemia, lymphoma, and other diseases. In addition, Dako Denmark A/S offers antibodies, which are used to measure the concentration of protein in blood, urine, and cerebrospinal fluid. It has collaboration with Genentech, OSI Pharmaceuticals, and Roche for the clinical development and application for a Premarket Approval Supplement and CE marking of EGFR pharmDx for use of the EGFR pharmDx test as a potential aid in the assessment of non-small cell lung cancer patients considered for treatment with Tarceva. The company was founded in 1966 and is headquartered in Glostrup, Denmark. Dako was acquired by Agilent Technologies in 2012.

Adamo Telecom

Acquisition in 2016
Adamo is a telecom operator in Spain offering ultra high speed Internet via Fiber To The Home across Spain (Catalonia, Valencia, , Madrid, Andalucia...). We offer the highest speed in Spain, 1000 Mbit/s Internet access and our origin is Swedish. Coverage: Alicante, Almería, Asturias, Badajoz, Barcelona, Burgos, Cantabria, Castellón, Córdoba, Cuenca, Gerona, Granada, Guadalajara, Lérida, Lugo, Madrid, Navarra, Palencia, Sevilla, Tarragona, Toledo, Valencia, Valladolid & Vizcaya.

Restaurant Technologies

Acquisition in 2011
Restaurant Technologies is the leading foodservice industry partner, proudly serving more than 30,000 quick-service and full-service restaurant chains, independent restaurants, grocery delis, hotels, casinos, universities and hospitals, nationwide. Restaurant Technologies helps foodservice operators make safer, smarter, more efficient and more sustainable kitchens through their cooking oil and hood and flue management solutions. Total Oil Management automates the cooking oil process from storage and handling to filtration, monitoring and disposal of used cooking oil. AutoMist® automates hood and flue cleaning, and Grease LockTM hood filters slow grease build-up. Headquartered in Mendota Heights, Minn., Restaurant Technologies is a privately held company, currently operates 41 depots and has more than 1,000 employees serving customers across the United States.
Sapiens Steering Brain Stimulation GmbH is an emerging medical device company whose mission is to deliver superior solutions for deep brain stimulation (DBS) therapy. Sapiens' ambition is to provide a unique, high-resolution, and MRI- compatible DBS system that will improve patient comfort and therapeutic outcome, initially for patients with Parkinson's disease. Sapiens, with offices in Eindhoven, the Netherlands and Munich, Germany, is founded in 2011 as a spin-out of Royal Philips Electronics. Its steering brain stimulation (SBS) system and image-guided programming are based upon patented technologies.

LUMA Vision

Series A in 2021
OneProjects Design and Innovation Ltd. develops healthcare technologies for the treatment of cardiac arrhythmias. It offers VERAFEYE, a connected platform technology to revolutionize the treatment of AFib and cardiac arrhythmias. The company was incorporated in 2017 and is based in Dublin, Ireland.

AviadoBio

Series A in 2021
AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

DNA Script

Series C in 2021
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

ISS

Acquisition in 2005
The ISS Group was founded in Copenhagen in 1901 and has grown to become one of the world’s leading Facility Services companies. ISS offers a wide range of services such as: Cleaning, Catering, Security, Property and Support Services as well as Facility Management. Global revenue amounted to DKK 74.1 billion in 2014 and ISS has more than 510,000 employees and local operations in more than 50 countries across Europe, Asia, North America, Latin America and Pacific, serving thousands of both public and private sector customers. ISS employees create value by working as integrated members of our clients’ organisations. A key component of the ISS HR strategy is developing capable employees in all functions. Team spirit and self-governance are encouraged, as is voluntary participation in additional training and multidisciplinary workflows. Besides developing their employees, ISS ensures compliance with Health, Safety and Environment (HSE) regulations. ISS demonstrates their social and ethical commitment through the ISS Code of Conduct, their membership in the UN Global Compact and by honoring the principles laid down in the Union Network International (UNI) agreement.

Cast & Crew

Acquisition in 2018
Founded in 1976, Cast & Crew began modestly as a small business that provided payroll services to the commercial and the music business. Today, with offices in Burbank, New York, Albuquerque, Atlanta, Baton Rouge, Detroit, Toronto and Vancouver, Cast & Crew has grown into a leading provider of payroll service for the Motion Picture, Television and Commercial Industries. Cast & Crew provides these same industries with its highly regarded PSL family of production accounting software. Thanks to our knowledgeable and experienced staff, Cast & Crew has developed the most stable and sophisticated production accounting software available on the market. We were the first in our field to provide 24/7 on-line support as well as electronic interfacing of payroll data with our proprietary software. PSL3 brings the convenience of the internet to production accounting. Responsiveness is where client services begin. Cast & Crew has built a reputation that's unmatched in its ability to respond quickly, and to address and resolve client issues promptly. This commitment is our trademark and our absolute first priority. We've built long lasting client relationships based on mutual reliance, integrity and trust. The people who work at Cast & Crew are the "hallmark" of our company. Their vast knowledge and extensive experience in the industry are what makes Cast & Crew the best in the business.

BBS Automation

Private Placement in 2018
BBS Automation is a provider of flexible and high-quality automation solutions for complex manufacturing and testing processes. With close to 550 employees across production sites in Germany, China, Malaysia and the US, BBS Automation partners with blue chip customers on a global scale.

Immunic Therapeutics

Series A in 2016
Immunic is a developer of oral drugs intended to help in the treatment of chronic inflammatory diseases. The company's drugs help to develop a small molecule immune modulators that block T helper type 1- and type 17-mediated immune and build autoimmune responses to treat conditions including inflammatory bowel disease (IBD) or psoriasis, enabling physicians to treat their patients in an enhanced way.

Pronota

Series A in 2006
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.

BMEYE

Series A in 2006
BMEYE B.V., a non-invasive cardiovascular monitoring company, engages in the research and development of medical technologies for cardiovascular monitoring in the Netherlands and internationally. It offers finger arterial pressure and cardiac output technologies. The company's products include Finapres, a non-invasive continuous finger blood pressure monitor; Portapres, an ambulatory non-invasive continuous finger blood pressure monitor for measurements; Finometer, a stationary monitor with options for non-invasive brachial pressure and beat-to-beat hemodynamics; and BeatScope, a software package for the analysis of arterial pressure waveforms. Its products also comprise Modelflow, a model-based measurement method to compute the aortic flow waveform and cardiac outout from an arterial blood pressure waveform; Space instrumentation, a version of finger blood pressure monitors; Cardiopres, an ambulatory device for research on the interaction of electrophysiology, hemodynamics, and respiration; and Oxyflow, a hemodynamics and oxygen delivery monitor for experimental applications. In addition, the company offers Nexfin, a non invasive blood pressure and cardiac output monitor, as well as ccNexfin for applications in various areas, such as cardiology, anesthesiology, sleep observation, physiology, neurology, and internal medicine; and emergency, acute, intensive, and intermediate care. It offers its products through a network of distributors. BMEYE B.V. was founded in 2005 and is based in Amsterdam, the Netherlands.

Koole Terminals

Acquisition in 2011
Koole is an independent international storage and transport company specialising in vegetable oils and fats, oleochemicals, waxes, biodiesel, base oils, non-hazardous chemicals and minerals.

Mendor

Series B in 2011
Mendor is a Finnish company, committed to the design, development and marketing of advanced diabetes management products. Mendor has launched a revolutionary, discreet, easy to use, portable all-in-one blood glucose meter and web-based software application for the daily management of diabetes. Mendor has designed its products together with users and diabetes experts to address the needs of people with diabetes requiring regular blood glucose monitoring.

Com Hem

Acquisition in 2003
Com Hem is the largest cable company in Sweden. Com Hem offers affordable, high quality, comprehensive services for television, broadband and telephone service to individuals and businesses. Since October 2013 delivers Com Hem TV service TiVo is the only player on the Swedish market, including TiVoToGo ™ app that allows Com Hem's customers can watch TV wherever they want through their eReader and phones. Com Home was founded in 1983, has approximately 950 employees, headquartered in Stockholm and controlled by BC Partners.

Arvelle Therapeutics

Series A in 2019
Arvelle Therapeutics GmbH, a biopharmaceutical company, focuses on solutions for patients suffering from CNS disorders. It is involved in the development and commercialization of cenobamate, an investigational antiepileptic drug in the European market. The company was founded in 2019 and is headquartered in Zug, Switzerland.

Banking Circle

Acquisition in 2018
A fully licensed bank, Banking Circle is a next-generation provider of mission-critical financial services infrastructure leading the rise of a super-correspondent banking network. Banks and Payments businesses can access a range of banking services - multi-currency bank accounts, local clearing, cross border payments and flexible business lending, compliantly and securely - without the need to build their own infrastructure and correspondent banking partner network. Bespoke, flexible, scalable and futureproofed solutions enable financial services businesses to do what they’re really good at – serving the end client successfully and efficiently – thereby allowing them to seize market opportunities. Bypass old, bureaucratic and expensive systems and enable global banking services for your clients. Financial infrastructure you can bank on.

EdgeConneX

Acquisition in 2020
Edge Services provide Space, Power & Connectivity to deliver digital content like never before. With EdgeConneX, data delivery is optimized by placing Edge Data Centers®, Edge Small Cells and Edge PoPs® at the most critical locations—as close as possible to the end user’s point of access. By using our services, digital content is delivered with higher performance and lower latency to any device, anywhere.

SeeQC

Private Placement in 2020
SeeQC, Inc. develops a digital quantum computing platform for businesses globally. It designs, tests, and manufactures quantum-ready superconductors. The company serves machine learning/AI, logistics optimization, quantum chemistry, pharmaceuticals, and fintech industries in the United States and Europe. SeeQC, Inc. was incorporated in 2018 and is based in Elmsford, New York. It has facilities in London, United Kingdom; and Naples, Italy.

Musti ja Mirri Oy

Acquisition in 2014
Musti ja Mirri Group (MMG) is the leading pet specialty retailer in Nordic countries. MMG’s product assortment comprises a complete range of pet supplies and accessories related to the pets’ well-being as well as pet foods. The chain has 127 stores in Finland and Sweden. MMG generated turnover of EUR 81 million in the year to September 2014 with 500 employees.

Salcomp

Acquisition in 1999
Salcomp Plc engages in the development and manufacture of power supplies. The company’s power supplies include batteries, rechargeable batteries, and chargers for mobile phones and electronic equipment, as well as for kinetic power supplies, photocells, and fuel cells. It also offers its charging solutions for cameras, navigators, tablets, notebooks, routers, point-of-sales devices, gateways, set-top-boxes, lighting, and other electronic applications. The company sells its chargers under the CHARGZ brand name to mobile phone manufacturers, as well as to other selected manufacturers and retail chains in the electronics business. It primarily operates in Brazil, China, Finland, India, and South Korea. The company was founded in 1975 and is headquartered in Salo, Finland. As of August 27, 2019, Salcomp Plc operates as a subsidiary of Lingyi iTech (Guangdong) Company.

Sequana Medical

Series C in 2015
Sequana Medical NV, a commercial stage medical device company, focuses on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure in Switzerland, Germany, and internationally. Its products include alfapump, a treatment solution for the management of liver refractory ascites and malignant ascites; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with volume overload due to heart failure. The company was founded in 2006 and is headquartered in Ghent, Belgium.

Merus

Series B in 2013
Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.

Wolt

Series E in 2021
Wolt makes it incredibly easy to discover and get great food, delivered to home or office. The Helsinki-based company has raised $280M in funding from investors such as ICONIQ Capital, Highland Europe, 83North, EQT Ventures and Goldman Sachs.

Solarpack

Acquisition in 2021
Solarpack focuses in the development and operation of large-scale photovoltaic solar projects. The company also has a consulting department that advises international customers in all areas of solar photovoltaic energy. The company global divisions which are development and construction, power generation, and services, represent an attractive and well-balanced combination of long term stable revenues with less recurrent yet highly profitable activities. It operates and maintains 13 plants, with a total capacity of 160 MW, and provides asset management services for a total of 302 MW of projects. The company also has a diversified geographical presence and employs over 140 people in 10 countries. Founded on 2005, Solarpack is a solid and solvent company, capable of executing quality and valuable projects for the society and the environment. It contributes directly to the social development of the communities and markets in which it operates, through the creation of economic value, and also through the generation of quality employment and through the social projects it promotes. It is headquartered in Getxo, Vizcaya in Spain.

Blikk Holding

Acquisition in 2021
The blikk group is a growing network of radiological, nuclear medicine and nephrology practices using dialysis. As a reliable partner for patients and referring physicians, the practices of the association make a significant contribution to high-quality medical care. They all share the common claim to the highest quality and excellent education and training of medical and non-medical staff in all disciplines.

FlowCardia

Series C in 2007
FlowCardia, Inc. is a medical device company founded in 2002 to design and develop a portfolio of innovative, catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. Chronic Total Occlusions (CTOs) are considered one of the last major clinical challenges in interventional therapy. The historic absence of safe and effective CTO recanalization devices is a major reason a large number of patients are still referred to coronary and peripheral bypass surgery and lower limb amputation.
Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products. The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enabling bladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials. It was established in Galway, Galway in 2013.

4-Antibody AG

Seed Round in 2004
4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.

DNage

Series A in 2005
DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).

Cardiac Dimensions

Private Placement in 2018
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

Prosensa

Series A in 2007
Prosensa is a biotech company also known as Ribpharm Inc dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics. During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology. Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.

Simplify Medical

Private Placement in 2017
Simplify Medical designs, develops, and manufactures cervical artificial discs for use in the spine. It offers an MRI compatible motion preserving artificial cervical disc that is used to treat single level symptomatic cervical disc disease. The company provides its products for skeletally mature patients for reconstruction of the disc at one level from C3-C7 following single-level discectomy for intractable radiculopathy, such as arm pain or a neurological deficit. Simplify Medical was founded in 2015 and is based in Mountain View, California.

Xeltis

Series B in 2015
Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.

Skykon A/S

Debt Financing in 2009
Skykon A/S is a privately held company that manufactures foundations, towers, blade tooling and composite components for blades in wind turbines.

EEW Energy from Waste

Merger/Acquisition in 2015
EEW Energy from Waste GmbH, through its subsidiaries, is engaged in waste incineration, and the production of power and heat from waste. The company designs, builds, and operates waste incineration plants. It generates climate-neutral electric power from waste; thermal energy from waste conserves fossil fuels; and power from steam. EEW Energy from Waste GmbH was formerly known as E.ON Energy from Waste AG. The company was founded in 1873 and is based in Helmstedt, Germany. As of March 2, 2016, EEW Energy from Waste GmbH operates as a subsidiary of Beijing Enterprises Holdings Limited.

Dentconnect

Acquisition in 2017
DentConnect is a fast-growing platform of dental clinics, with activities in the Netherlands, Belgium, Denmark, Germany and Italy. DentConnect is headquartered in the Netherlands and serves over one million patients through its pan-European network of over 220 clinics. DentConnect acts as a multi-functional service organization for these clinics, allowing the dentists to fully focus on providing patients with the best possible care. DentConnect Shared Service Center supports and facilitates dentists with HR, Finance and administration, quality and care management, procurement, marketing and communication and general management.